Johan Wäborg, CEO, Iconovo
| Published May 22, 2025

Iconovo focuses on commercialization

Iconovo is currently undergoing a strategic reorganization in connection with the company's five inhaler platforms reaching development maturity. In an interview with BioStock, CEO Johan Wäborg talks about how the restructuring strengthens the team's focus and efficiency, and how the ongoing rights issue of SEK 36,6 million will be used to drive the company towards new commercial goals. He also shares the company's priorities and the biggest challenges on the way forward.

Watch the interview with the CEO Johan Waborg below.

BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.

This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which has been published and published on the said company's website.